Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP2K1 | Q02750 | 17/20 | 0.71 |
| ▸ | MAP2K2 | P36507 | 5/20 | 0.64 |
| ▸ | CSNK2A2 | P19784 | 2/20 | 0.55 |
| ▸ | RAF1 | P04049 | 1/20 | 0.55 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.55 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.55 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.55 |
| ▸ | CSNK2A3 | Q8NEV1 | 1/20 | 0.55 |
| ▸ | AURKC | Q9UQB9 | 1/20 | 0.55 |
| ▸ | CAMK2A | Q9UQM7 | 1/20 | 0.55 |
| ▸ | PIM1 | P11309 | 1/20 | 0.53 |
| ▸ | CAMK2B | Q13554 | 1/20 | 0.53 |
| ▸ | SMC2 | O95347 | 1/20 | 0.51 |
| ▸ | EGFR | P00533 | 1/20 | 0.51 |
| ▸ | SMC1A | Q14683 | 1/20 | 0.51 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.51 |
| ▸ | Q6ZSR9 | Q6ZSR9 | 1/20 | 0.51 |
| ▸ | BMP2K | Q9NSY1 | 1/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.50 |
| ▸ | BRAF | P15056 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6829209 | 0.91 | MAP2K1 (0.75) | MAP2K1MAP2K2PIM1CAMK2BMAPK1 | |
| SCHEMBL5990081 | 0.86 | MAP2K1 (0.71) | MAP2K1MAP2K2CSNK2A2RAF1PDGFRB | |
| SCHEMBL4861211 | 0.86 | MAP2K1 (0.82) | MAP2K1MAP2K2CSNK2A2RAF1PDGFRB | |
| SCHEMBL5989954 | 0.83 | MAP2K1 (0.70) | MAP2K1MAP2K2CSNK2A2RAF1PDGFRB | |
| SCHEMBL5992088 | 0.83 | MAP2K1 (0.70) | MAP2K1MAP2K2CSNK2A2RAF1PDGFRB | |
| SCHEMBL6395495 | 0.83 | MAP2K1 (0.72) | MAP2K1MAP2K2CSNK2A2RAF1PDGFRB | |
| SCHEMBL4748560 | 0.83 | MAP2K1 (1.00) | MAP2K1MAP2K2PIM1CAMK2BMAPK1 | |
| SCHEMBL6826546 | 0.82 | MAP2K1 (0.74) | MAP2K1MAP2K2PIM1CAMK2BMAPK1 | |
| SCHEMBL6830448 | 0.82 | MAP2K1 (0.74) | MAP2K1MAP2K2PIM1CAMK2BMAPK1 | |
| SCHEMBL6826762 | 0.81 | MAP2K1 (0.77) | MAP2K1MAP2K2PIM1CAMK2BMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1467965-A1 | N-(4-SUBSTITUTED PHENYL)-ANTHRANILIC ACID HYDROXAMATE ESTERS | Warner-Lambert Company LLC (US) | 2004-10-20 | — | — | EP | claimed |
| US-6770778-B2 | MAP KINASE INHIBITORS; ANTICARCINOGENIC AGENTS; RESTENOSIS, PSORIASIS, AND ATHEROSCLEROSIS TREATMENT; ANTIARTHRITIC AGENTS; CARDIOVASCULAR DISORDERS | PFIZER INC | 2004-08-03 | — | — | US | claimed |
| US-20030232889-A1 | N-(4-substituted phenyl)-anthranilic acid hydroxamate esters | WARNET-LAMBERT COMPANY LLC | 2003-12-18 | — | — | US | claimed |
| WO-2003062189-A1 | N-(4-SUBSTITUTED PHENYL)-ANTHRANILIC ACID HYDROXAMATE ESTERS | WARNER-LAMBERT COMPANY LLC (US) | 2003-07-31 | — | — | WO | claimed |
| EP-1467965-A1 | N-(4-SUBSTITUTED PHENYL)-ANTHRANILIC ACID HYDROXAMATE ESTERS | Warner-Lambert Company LLC (US) | 2004-10-20 | — | — | EP | disclosed |
| US-6770778-B2 | MAP KINASE INHIBITORS; ANTICARCINOGENIC AGENTS; RESTENOSIS, PSORIASIS, AND ATHEROSCLEROSIS TREATMENT; ANTIARTHRITIC AGENTS; CARDIOVASCULAR DISORDERS | PFIZER INC | 2004-08-03 | — | — | US | disclosed |
| US-20030232889-A1 | N-(4-substituted phenyl)-anthranilic acid hydroxamate esters | WARNET-LAMBERT COMPANY LLC | 2003-12-18 | — | — | US | disclosed |
| WO-2003062189-A1 | N-(4-SUBSTITUTED PHENYL)-ANTHRANILIC ACID HYDROXAMATE ESTERS | WARNER-LAMBERT COMPANY LLC (US) | 2003-07-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030232889-A1 | N-(4-substituted phenyl)-anthranilic acid hydroxamate esters | AADAC, EGLN3, HCAR2 | MAP2K1 4732/4885MAP2K2 4641/4885CSNK2A2 3707/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.